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Background: Shifts in intracellular arginine (Arg) and sulfur amino acid (SAA) redox metabolism modulate
macrophage activation, polarization and phenotype. Despite their importance in inflammation and redox regulatory
pathways, comprehensive analysis of these metabolic networks was not previously possible with existing analytical
methods.
Methods: The Arg/thiol redox LC-MS/MS metabolomics assay permits simultaneous assessment of amino acids and
derivative products generated from Arg and SAA metabolism. Using this assay, LPS-induced changes in
macrophage amino acid metabolism were monitored to identify pathway shifts during activation and their linkage
to cellular redox regulation.
Results: Metabolite concentrations most significantly changed after treatment of a macrophage-like cell line (RAW)
with LPS for 24 hrs were citrulline (Cit) (48-fold increase), ornithine (Orn) (8.5-fold increase), arginine (Arg) (66%
decrease), and aspartic acid (Asp) (73% decrease). The ratio Cit + Orn/Arg + Asp (CO/AA) was more sensitive to LPS
stimulation than other amino acid ratios commonly used to measure LPS-dependent inflammation (e.g., SAM/SAH,
GSH/GSSG) and total media NOx. The CO/AA ratio was also the first ratio to change significantly after LPS treatment
(4 hrs). Changes in the overall metabolomic profile over time indicated that metabolic pathways shifted from Arg
catabolism to thiol oxidation.
Conclusions: Simultaneous quantification of Arg and SAA metabolic pathway shifts following LPS challenge of
macrophage indicate that, in this system, the Arg-Citrulline/NO cycle and arginase pathways are the amino acid
metabolic pathways most sensitive to LPS-challenge. The cellular (Cit + Orn)/(Arg + Asp) ratio, which summarizes
this pathway, was more responsive to lower concentrations of LPS and responded earlier than other metabolic
biomarkers of macrophage activation including GSH redox. It is suggested that the CO/AA ratio is a redox-
independent early biomarker of macrophage activation. The ability to measure both the CO/AA and GSH-redox
ratios simultaneously permits quantification of the relative effects of LPS challenge on macrophage inflammation
and oxidative stress pathways. The use of this assay in humans is discussed, as are clinical implications.
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While a direct causal link between inflammation/oxida-
tive stress and disease has not been proven, heightened
systemic oxidative and inflammatory stress is strongly
associated with the transition from health to disease [1-3].
For example, prospective epidemiological studies indicate
that increases in oxidative stress and inflammation are
associated with elevated risk of cognitive decline, cardio-
vascular disease, and cancer [4-8].
Non-proteinogenic metabolism of amino acids is a cen-
tral part of the inflammation and redox environment. Ar-
ginine (Arg) and sulfur amino acid (SAA) metabolism play
critical roles in regulating the physiological response to in-
jury and oxidative stress [9-12]. These pathways are illu-
strated in Figure 1 and briefly described below.
Arginine (Arg) is a conditionally essential amino acid
whose nutritional requirement is increased during in-
flammation [9-11]. During inflammation, Arg is catabo-
lized primarily to citrulline (Cit) (Figure 1: rectangle)
and ornithine (Orn) (Figure 1: rectangle) to generate
NO, urea and the polyamines putrescine (Put), spermi-
dine (Spd), and spermine (Spm) (Figure 1: hexagons)
[9-11]. The products of Arg catabolism directly modu-
late inflammation by controlling endothelial function,
leukocyte recruitment and activation, innate immunity,
and extracellular matrix remodeling [9-11].
Metabolism of sulfur amino acids (SAA) occurs
through four interconnected metabolic pathways - trans-
methylation, transsulfuration, GSH synthesis, and the γ-
glutamyl-cycle (Figure 1: ovals) [13,14]. As shown, each
of these cycles produce one sulfhydryl (−SH) containing
compound. These are, respectively, homocysteine (Hcy),
cysteine (Cys), glutathione (GSH) and cysteinylglycine
(Cysgly) (Figure 1: grey ovals). The homeostatic balance
of these compounds is important for cellular redox regu-
lation [15,16]. Excess accumulation of Hcy and Cys is
pro-inflammatory in cells [17-20] and is also associated
with increased cardiovascular disease risk [12,21-23].
GSH is the principal thiol antioxidant, and a key regula-
tor of cellular protein thiol redox states [15,16]. In
addition to its direct antioxidant function, the synthesis
of GSH from its rate-limiting substrate Cys minimizes
the toxicity of excess Cys accumulation and acts as a cel-
lular Cys reserve [15,16]. In fact, the release of Cys on
GSH breakdown is an important means of inter-organ
Cys trafficking [24]. GSH is only catabolized by
γ-glutamyl transpeptidase (GGT), which generates
Cysgly dipeptide [24]. Microsomal dipeptidase enzymes
hydrolyze Cysgly to yield Cys. Because Cysgly does not
accumulate in cells, it does not contribute significantly
to cellular redox regulation directly. GGT expression is
increased in conditions of inflammation and oxidative
stress and acts as an important part in the cellular redox
regulation [25-27].The Arg and SAA metabolic pathways are also
impacted by metabolism of amino acids that are not dir-
ectly a part of those pathways. For example, on Arg defi-
ciency, amino acids such as aspartate, glutamate and
proline (Figure 1: circles) can be utilized to regenerate
Arg [28,29]. Cystathionine (Cysth), a precursor of Cys, is
synthesized from homocysteine and serine [13,14]. Gly
and Glu are also required for GSH formation. Thus, a
comprehensive analysis of amino acids, in addition to
directly focusing on metabolites in the Arg and SAA
pathways, may be useful in identifying factors that con-
tribute to Arg and SAA pathway shifts on inflammation
and oxidative stress.
While several sensitive analytical techniques are avail-
able that quantify GSH redox states and secondary Arg
metabolic intermediates [30-35], the method utilized
here is the first that permits simultaneous monitoring of
all amino acids and the major secondary metabolites in
both Arg and SAA metabolism.
Our Arg/thiol redox metabolomics assay combines an
isopropylchloroformate derivatization method previously
developed for analyzing 20 major amino acids [36] with
modifications that enable detection of reduced and oxi-
dized thiols with minimal ex-vivo oxidation [37]. The
assay targets the major amino acids and secondary meta-
bolic products of Arg and SAA shown in Figure 1, a total
of 34 metabolites. This report presents results of experi-
ments using RAW murine macrophage-like cells to test
the sensitivity of this assay in detecting metabolic shifts
in both oxidative stress and inflammation pathways oc-
curring following a challenge with bacterial LPS.Methods
Reagents
Arginine (Arg), Citrulline (Cit), Putrescine (Put), Spermi-
dine (Spd), Spermine (Spm), methionine (Met), methi-
onine sulfoxide (MetSO), S-adenosylmethionine (SAM),
S-adenosylhomocysteine (SAH), homocysteine (Hcy), ho-
mocystine (Hcy2), cystathionine (Cysth), cysteine (Cys),
cystine (Cys2), glutathione (GSH), glutathione-disulfide
(GSSG), cysteinyl-glycine (Cysgly), cysteinyl-glycine di-
sulfide (Cysgly2), glycine (Gly), glutamine (Gln), and glu-
tamate (Glu), of highest analytical grade were purchased
from Sigma (St. Louis, MO). Homoglutathione was pur-
chased from BACHEM. Stable isotopes, methionine-
methyl-D3, Homocystine (3,3,3’,3’,4,4,4’,4’-D8), Cystine
(3,3,3’3’-D4), and Glycine (
13C2,
15N) were purchased from
Cambridge Isotopes. S-Adenosylmethionine (methyl-D3)
was obtained from CDN Isotopes (Quebec, Canada). All
HPLC solvents were of the analytical grade available
from Fisher Scientific. The EZ-FAAST kit used for sam-
ple and standard derivatization was purchased from Phe-
nomenex (Torrance, CA).
Figure 1 Metabolites and their metabolic pathway networks measured by the Arg/Thiol Redox Metabolomics Assay. The assay covers
nearly all Arg metabolic pathways (rectangle), including the arginase, Cit-NO cycle, and polaymine pathways (hexagon). Also shown are sulfur
amino acid derived sulfhydryl containing redox metabolites (grey ovals), and names of enzymes involved in the synthesis pathways.
Argininosuccinate (dotted rectangle box) was not measured. Some major amino acids (circles) were measured but are not shown in this figure
(See Table 1 for a complete list of analytes quantified). Compounds that were significantly decreased or increased after 24 hrs of treatment with
LPS (1000 ng/ml) are highlighted with - or +, respectively. Abbreviations: Alanine – Ala; Arginine – Arg; Asparagine – Asn; Aspartate – Asp;
Argninosuccinate Lyase - ASL; Argininosuccinate Synthetase – ASS; Betaine Hydroxymethyl Transferase - BHMT; Citrulline – Cit; Cysteine – Cys;
Cystathionine Beta-synthase - CBS; Cystathionine Lyase - CL; γ-Glutamyl Transpeptidase – GGT; γ-Glutamylcysteine Ligase – GCL; Glutathione –
GSH; Glutathione disulfide – GSSG; Glutathione synthase - GS ; Glutamate – Glu; Glutamine – Gln; Glutamine Synthase - Gln Syn; Glycine – Gly;
Histidine – His; Homocysteine – Hcy; Methionine – Met; Methionine Adenosyl Transferase – MAT; Methyl Transferase - MT; Methionine Synthase -
MS; Nitric Oxide Synthase - NOS; Ornithine – Orn; Ornithine Decarboxylase - ODC; Proline - Pro; Putrescine – Put; Polyamine Oxidase - PAO; S-
adenosylmethionine – SAM; S-Adenosylmehtionine Decarboxylase - SAMDC; S-adenosylhomocysteine – SAH; S-Adenosylhomocysteine hydrolyase
- SAHH; Serine – Ser; Spermidine – Spd; Spermidine Synthase - Spd Syn; Spermine synthase - Spm Syn; Spermine – Spm; Spermidine/Spermine
N1 acetyltransferase - SSAT.
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RAW267.4 mouse macrophage cells (RAW) in phenol-
free Dulbecco’s minimal essential media (DMEM; Sigma)
containing 5% heat-inactivated fetal bovine serum (FBS)
were plated overnight in 6 well plates (2 × 106 cells/well).
To profile the concentration-dependent effects of LPS
on amino acid metabolism, plated cells were incubated
in media treated with or without 0.1, 1, 10, 100, and
1000 ng/ml bacterial lipopolysaccharide (LPS; type 055:
B5) at 37°C for 24 hrs. For the time course experiments,cells were challenged with 10 ng/ml LPS at 37°C for 2, 4,
or 6 hrs. To quantify amino acid metabolites, cells were
detached from the plate with Trypsin and washed twice
with pre-warmed phosphate buffered saline. Cell pellets
were resuspended in 200 μl PBS buffer; cell number and
viability were checked by tryphan blue exclusion assay.
To quantify redox states of thiol amino acid metabolites,
cell pellet suspensions were mixed with an equal volume
of 20 mM iodoacetamide (IAM) dissolved in 0.1 M Tris-
Cl buffer (pH 8.0) for 1 hr. Following IAM treatment,
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ume of 10% perchloric acid containing 0.2 mM DTPA
and centrifuged at 13000 rpm for 5 min. Acidified super-
natants were collected and stored at −80°C until
analysis.Derivatization procedures
Stock solutions (10 mM) of amino acid standards were
prepared in 5% perchloric acid containing 0.5 mM
DTPA. An internal standards mix contained 10 μM solu-
tion of arginine (15N2), glycine (
13C2,
15N), methionine
(methyl-D3), S-adenosylmethionione (methyl-D3), cystine
3,3’3’3’-D4) and homocystine (3,3,3’3’4,4,4’4’-D8) stable
isotopes. Standards were diluted to working concentra-
tions of 0.05, 0.5, 5, and 50 μM in 5% PCA solution.
Derivatization of acidified cell lysates and media was per-
formed as previously described [37]. Briefly, 20 μl of in-
ternal standard solution was added to acidified cell lysates
(180 μl). To these samples, 70 μl of KOH/tetrahydroborate
buffer was added and centrifuged at 12,000 × g. Super-
natants (200 μl) were derivatized using the EZ-FAAST
Kit per manufacturer’s protocol.HPLC conditions
HPLC analysis was performed on the Shimadzu LC-
10AD HPLC system equipped with the SIL-10 AVP
auto-sampler, and two LC-AD10 pumps. The chromato-
graphic separation was carried out on a 25 mm X 2 mm
column supplied by EZ-FAAST (Phenomenex CA). The
mobile phase was composed of methanol:water (80:20 v/v)
containing 1 mM ammonium formate and the total
flow rate was set at 0.25 ml/min.10 μl of each standards
plus samples solution was injected with a total run time
of 15 min.Mass spectrometer settings
Detection of derivatized metabolites and internal stan-
dards was carried out with Quattro LC mass spectrom-
eter (Micromass; Waters, MA) in electrospray positive
ionization mode. Results were quantified using the Mas-
sLynx 3.3 software. Capillary voltage was set to 3 kV,
source temperature to 130°C, and nebulizer gas
temperature to 400°C. The nebulizer and analysis cell
gas flows (both nitrogen) were set at 80 and 800 L/h, re-
spectively. The low and high mass resolutions were fixed
at 15 for both the first and third quadrupole mass analy-
zers. The collision gas (argon) pressure in the second
quadrupole was set at 1.5 mbar. The photomultiplier
was fixed at 650. The dwell time and the interchannel
delay were fixed at 0.2 and 0.01 s, respectively. The opti-
mized cone voltages and collision energy settings for me-
tabolites detected are listed in Additional file 1: Table S1.Statistical analysis
Statistical significance (p < 0.05) was determined using
two-way ANOVA followed by a Dunnett’s post hoc tests
for multiple comparisons between controls and cells
treated with different concentrations of LPS and at dif-
ferent time points.
Results
LPS-dependent changes in the RAW macrophage amino
acid profile
LPS activates macrophage via the classical activation
pathway by initiating the Toll-like receptor 4 (TLR-4)
and MD2-dependent redox sensitive inflammatory sig-
naling cascade [38]. In LPS-stimulated macrophages,
changes in gene expression have been detected as early
as 2 hrs after challenge for early-response genes, whereas
changes in late-response genes have not been detected
until ~24 hrs after challenge [39].
As shown in Table 1, after 24 hrs incubation of RAW
cells in the presence of 1 μg/ml LPS, cellular concentra-
tions of 60% (18/34) of the metabolites measured were
significantly altered compared to untreated cultures;
concentrations of 11 increased, while 7 decreased. Meta-
bolites that increased (Table 1) were primarily inter-
mediates involved in either Arg or SAA metabolism
(Figure 1). The two greatest increases were for Cit and
Orn, intermediates produced by NOS and arginase
enzymes respectively. Of these two metabolites, Cit
exhibited the larger increase, with levels rising from 0.2
± 0.02 nmol/mg protein in untreated cells to 10.3 ± 1.8
nmol/mg in LPS-treated cells (p < 0.0001). Orn, an
arginase-mediated metabolite of arginine (Figure 1),
increased to a lesser extent than Cit, approximately 7-
fold (Table 1). Put, the rate-limiting substrate for cellular
polyamines (Figure 1), also increased to a similar extent,
approximately 5-fold (Table 1). To rule out the possibil-
ity of artifacts introduced by IAM incubation, intracellu-
lar concentrations of Arg, Cit and Orn were extracted
with perchloric acid without IAM pretreatment with
similar results (Additional file 2: Figure S1). This sug-
gests that IAM did not cause incomplete arginase inacti-
vation during the incubation period and it did not
contribute to the LPS-dependent increase in intracellular
Orn.
Though their response was modest in comparison to
Arg-related intermediates, certain SAA metabolites were
also responsive to LPS treatment. Most notably, Cys, the
rate-limiting precursor of cellular GSH, increased
several-fold in LPS treated cells, from 2.1 ± 0.7 to
6.2 ± 1.7 nmol/mg protein. Gln is metabolized to form
Glu, which serves as a precurser to Arg and GSH. Gln
concentration was increased by ~60% in LPS-treated
compared to untreated cells (Table 1). Met and Hcy also
increased by ~35 and 65%, respectively, following LPS
Table 1 LPS-induced changes in cellular amino acid metabolites
Metabolite Controla (nmol/mg protein) LPSb (nmol/mg protein) % CHANGEc from Control Pathwayd Sige
Cit 0.2 ± 0.02 10.3 ± 1.8 5050.0 Arg Met < 0.0001
Orn 0.7 ± 0.3 5.78 ± 0.8 752.9 Arg Met < 0.0001
Put 1.2 ± 0.2 7.5 ± 2.4 525.0 Arg Met < 0.0001
Cys 2.1 ± 0.7 6.2 ± 1.7 195.2 SAA Met < 0.01
Gln 6.2 ± 0.5 16.1 ± 0.5 159.7 Arg Met < 0.01
Ile+Leu 1.3 ± 0.2 3.3 ± 0.8 153.8 BCAA < 0.05
Phe 0.6 ± 0.6 1.0 ± 0.3 66.7 EAA < 0.05
Hcy 0.03 ± 0.01 0.05 ± 0.02 66.7 SAA Met < 0.05
Ser 1.6 ± 0.2 2.2 ± 0.4 37.5 SAA Met < 0.05
Met 4.0 ± 0.4 5.4 ± 0.3 35.0 SAA Met < 0.05
GSSG 0.4 ± 0.1 0.5 ± 0.1 25.0 SAA Met < 0.05
Asn 2.3 ± 0.3 2.6 ± 0.5 13.0
Pro 5.4 ± 1.6 6.0 ± 1.3 11.1
Lys 13.23 ± 2.85 14.61 ± 4.34 10.4
Ala 3.3 ± 0.8 3.6 ± 0.34 9.1
His 1.5 ± 0.5 1.6 ± 0.2 6.7
Spd 13.3 ± 2.1 13.7 ± 2.3 3.0
Trp 0.4 ± 0.1 0.4 ± 0.1 0.0
Tyr 0.7 ± 0.3 0.7 ± 0.24 0.0
Val 0.7 ± 0.3 0.7 ± 0.2 0.0
SAM 0.2 ± 0.04 2.2 ± 0.2 −7.1
Thr 9.2 ± 2.5 8.3 ± 1.9 −9.8
GSH 46.8 ± 2.4 37 ± 4.9 −20.9 SAA Met < 0.05
Glu 37.5 ± 3.8 24.9 ± 5.2 −33.6 SAA Met < 0.05
Gly 25.4 ± 1.0 16.0 ± 1.1 −37.0 SAA Met < 0.05
SAH 0.2 ± 0.03 0.1 ± 0.02 −50.0 SAA Met < 0.01
Spm 23.8 ± 1.5 8.23 ± 6.2 −65.4 Arg Met < 0.01
Arg 3.2 ± 0.13 1.1 ± 0.11 −65.6 Arg Met < 0.0001
Asp 57.8 ± 13.8 15.8 ± 4.0 −72.7 Arg Met < 0.0001
RAW macrophage cells (2 × 106) were incubated in the absence (control) or presence of 1 μg/ml LPS (LPS) for 24 hrs. Cellular metabolites were extracted and
analyzed as described in Methods. a,b - Metabolites quantified and their corresponding concentrations are listed. Values presented are averages from 5
experiments (mean ± SD). c- % change for each of the metabolites in LPS treated cells from control cultures are listed. d- Metabolic pathways for metabolites that
were significantly altered by LPS are listed. e- * denotes statistical significance of the differences detected.
Abbreviations: Alanine – Ala; Arginine – Arg; Arginine metabolism - Arg Met; Asparagine – Asn; Aspartate – Asp; Branched Chain Amino Acids - BCAA Citrulline – Cit; Cysteine –
Cys; Essential Amino Acids - EAA Glutamate – Glu; Glutamine – Gln; Glutathione – GSH; Glutathione disulfide – GSSG; Glycine – Gly; Histidine – His; Homocysteine – Hcy; Isoleucine
+Leucine – Ile-Leu; Lysine – Lys; Methionine –Met; Ornithine – Orn; Proline - Pro; Putrescine – Put; Phenylalanine – Phe; Sulfur Amino Acid Metabolism - SAA Met; S-
adenosylmethionine – SAM; S-adenosylhomocysteine – SAH; Serine – Ser; Spermidine – Spd; Spermine – Spm; Threonine – Thr; Tryptophan – Trp; Tyrosine – Tyr; Valine – Val.
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transmethylation pathway, which supplies Cys required
for GSH synthesis. Lastly, cellular concentrations of
GSSG, the homodisulfide of GSH, increased by ~25% in
LPS treated cells.
In addition to the 6 metabolites that increased by
more than 2-fold following LPS exposure, 7 compounds
were significantly decreased. Intracellular Arg and Asp
significantly decreased by 65.6 and 72.7% respectively.
Asp is a substrate required for Arg regeneration via the
argininosuccinate lyase pathway [29,40]. The decreasesin both Arg and Asp suggest that LPS imposes an acute
depletion of cellular Arg equivalents. Despite a signifi-
cant increase in cellular Put, cellular levels of polyamines
derived from Put decreased. SPM declined from 23.2 ±
1.5 nmol/mg protein in control cultures to 8.2 nmol/mg
protein in LPS treated cells. Cellular SAH, Gly, Glu and
GSH showed more modest declines following LPS treat-
ment. Compared to controls, LPS-treated cells contained
~50% less cellular SAH, a by-product of SAM methyla-
tion reactions. Concentrations of Glu and Gly, constitu-
ents of cellular GSH, both declined by ~30%. Cellular
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± 4.9 nmol/mg protein in LPS-treated cells. This ~20%
loss in cellular GSH, along with similar increases in
GSSG concentration, indicate that LPS treatment shifted
cellular thiol redox to a more oxidized state.
LPS concentration-dependent effects on Arg metabolism
Evidence suggests that the metabolic fate of Arg is a crit-
ical determinant of classical or alternative activation path-
ways in macrophage cells [9-11]. Effects on the steady-
state concentrations of Arg and two major Arg-derived
metabolites, Cit and Orn, were measured 24 hrs after
treatment with 0, 0.1, 1, 10, 100, and 1,000 ng/ml LPS
(Figure 2). As shown, significant declines in Arg and
increases in Cit were observed when LPS concentrations
were at 10 ng/ml and above. Orn also increased signifi-
cantly, but only at the two highest LPS concentrations.
The Cit/Orn ratio increased significantly at lower con-
centrations of LPS (1 ng/ml) than required to cause a
significant increase in either Cit or Orn individually. The
maximal increase in the Cit/Orn ratio was observed
when cells were treated with 10 ng/ml LPS. At higher
concentrations of LPS (100 and 1000 ng/ml), the cellular
Cit/Orn ratio decreased to 4.5 and 1.8 from the maximal
ratio of 6.6 obtained at 10 ng/ml LPS. The data indicate
that the increase in Orn, which occurred at concentra-
tions of LPS at or above 100 ng/ml, signals a shift in ArgFigure 2 NO formation in LPS-activated macrophage is regulated by
dependent effects of LPS on intracellular Arg (panel A) and its metabolic p
which indicates the balance between NOS and arginase dependent pathw
nitrate/nitrite (NOx; panel C) concentration. Raw cells (2 × 106 cells) were e
LPS at 37°C for 24 hrs.consumption toward urea generation. Orn is a precursor
to both proline and the polyamines spermidine and
spermine. The concentrations of Pro, and Spd remained
unchanged across all concentrations of LPS tested
(Table 2). Thus, while Orn increased at higher LPS con-
centrations, this did not result in increased generation of
its products.
Threshold concentrations of LPS
As shown in Table 1, LPS treatment for 24 hrs strongly
increased Arg metabolism. Though less prominent than
changes in the Arg pathway, SAA metabolites (notably
GSH, which indicates the redox state of the cell)
decreased following LPS treatment. These results sug-
gest that Arg and SAA metabolites are highly responsive
to LPS-dependent classical M1 activation and may be
useful as surrogate markers of inflammation.
The Arg and SAA metabolites that exhibited the great-
est change on LPS treatment were Arg, Asp, Orn, and
Cit. Arg and Asp exhibited the greatest decrease after
LPS treatment, while their products Orn and Cit exhib-
ited the greatest increase. We hypothesized that a ratio
of the sums of these metabolites: (Cit + Orn)/(Arg +
Asp), which we term the CO/AA ratio, would be highly
sensitive to metabolic shifts following LPS treatment.
The relative sensitivity of this ratio to LPS was compared
to several established amino acid ratios used aschanges in iNOS and Arginase activities. The concentration
roducts, Cit (panel B) and Orn (panel D) are shown. The Cit/Orn ratio,
ay is plotted in (panel E) and compared to the media total media
ither left untreated or incubated with 0.1, 1,10, 100 and 1000 ng/ml
Table 2 LPS-dependent changes in ornithine derived products
LPS Concentrations
Metabolite Control 0.1 ng/ml 1 ng/ml 10 ng/ml 100 ng/ml 1000 ng/ml
Orn 0.78 ± 0.20 1.07 ± 0.25 1.36 ± 0.31 1.47 ± 0.88 3.26 ± 0.24* 5.86 ± 0.83**
Put 1.21 ± 0.39 2.88 ± 0.98 6.05 ± 2.8** 7.94 ± 3.11** 9.56 ± 4.28** 9.31 ± 3.42**
Pro 5.45 ± 1.62 6.77 ± 1.36 7.81 ± 2.90 7.38 ± 1.98 7.07 ± 1.82 6.04 ± 1.33
Spd 13.32 ± 2.09 15.72 ± 2.28 13.67 ± 2.35 13.93 ± 2.09 13.66 ± 1.60 13.74 ± 2.38
Spm 23.82 ± 1.55 14.07 ± 3.05* 12.60 ± 2.48* 10.69 ± 2.75** 7.39 ± 1.86** 6.75 ± 2.04**
RAW cells (2 × 106) cells were incubated in the absence (control) or in the presence of 0.1, 1, 10, 100 and 1000 ng/ml LPS (LPS) for 24 hrs. Cellular metabolites
were extracted and analyzed as described in methods. Results are an average of 3 independent experiments. * and ** denotes p < 0.05 or p < 0.01, respectively.
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[40], GSH/GSSG [41,42], Spd/Spm [43], and Gln/Glu
[44]. In addition to these markers, the media concentra-
tion of NOx, was also measured because it is a
metabolite-independent measure of RAW cell activica-
tion and inflammation [45].
As shown in Figure 3, significant increases in total
media NOx following 24 hrs incubation with LPS were
detectable only when LPS concentrations were ≥ 100
ng/ml. The total media NOx concentration increased
from baseline values of 3.5 ± 0.5 μM to 5.8 ± 0.4 and 7.0
± 0.6 μM in cells treated with 100 and 1000 ng/ml LPS,
respectively. In contrast, 0.1 ng/ml LPS was sufficient to
cause a statistically significant 290 ± 166% increase in
the CO/AA ratio (p < 0.01). Further increasing LPS con-
centrations to 1, 10 and 100 and 1000 ng/ml caused the
intracellular CO/AA ratio to rise by 1241 ± 576, 2530 ±
945, 4497 ± 979, and 6775 ± 1969%, respectively.Figure 3 The cellular CO/AA ratio is the most sensitive amino acid-ba
AA ratio to varying concentrations of LPS was compared to total media nit
Raw cells (2 × 106 cells) were either left untreated or incubated with 0.1, 1,
concentrations and metabolite ratios obtained were normalized to baseline
plotted (mean ± SD; N = 6). The CO/AA ratio was the sole indicator that w
at higher LPS concentrations in a dose-dependent manner. At all concentr
other metabolic indices of macrophage activation. * denotes p < 0.05; ** dAs evident in Figure 3, the CO/AA ratio was most
sensitive to metabolic shifts following LPS treatment at
all concentrations tested. Significant alterations in other
amino acid metabolite markers were only observable
after treatment with at least 10 ng/ml LPS. At 10 ng/ml
LPS the Gln/Glu ratio increased by 280 ± 69%, whereas
the Spd/Spm ratio decreased by approximately 50%. As
shown, LPS-dependent changes in metabolite ratios
linked to cellular sulfur amino acid metabolism, such as
SAM/SAH and GSH/GSSG were only observed at LPS
concentrations ≥100 ng/ml.
Earliest detectable metabolic change following LPS
treatment
To ascertain the earliest time-point following LPS
treatment at which metabolic change was detected by
the CO/AA ratio as compared to the other biomarkers
discussed above, RAW cells were either left untreated orsed biomarker of LPS activation. The relative sensitivity of the CO/
rate/nitrite (NOx), Gln/Glu, SAM/SAH, GSH/GSSG, AND Spd/Spm ratios.
10, 100 and 1000 ng/ml LPS at 37°C for 24 hrs. Media NOx
levels in untreated cells and the % changes from baseline were
as significantly changed, even at 0.1 ng/ml LPS, and further increased
ations of LPS tested, the changes in CO/AA ratio were greater than
enotes p < 0.001.
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in Figure 4A, at this concentration of LPS, the CO/AA
ratio significantly increased by 171 ± 25% (p < 0.01) after
4 hrs following LPS treatment, and increased by 294 ±
42% at 6 hrs. In contrast, total media NOx concentra-
tions and cellular GSH/GSSG ratios remained un-
changed relative to controls. Glutamine/glutamate and
Spd/Spm ratios significantly increased 4 hrs following
LPS challenge (Figure 4B), however the SAM/SAH ratio,
which measures the cellular methylation capacity, did
not change during the first 6 hrs following LPS addition
(Figure 4B).
In summary, the CO/AA ratio changed significantly at
lower LPS concentrations and at earlier times following
challenge than the other metabolic indices of macro-
phage activation to which it was compared.
Discussion
In the present work, a comprehensive Arg/thiol redox
amino acid metabolomics assay was used to monitor
amino acid metabolic changes following LPS challenge
of RAW macrophage cells. The Arg-Cit-NO cycle and
arginase pathways were identified as most sensitive to
LPS. This assay was also useful in determining the tem-
poral relastionships between these pathways and cellular
redox regulation.
As shown in Table 1 and Figures 3–4, Arg, Asp, Cit
and Orn were most significantly affected by LPS treat-
ment. Since these metabolites are involved in Arg catab-
olism and synthesis, these results indicate that Arg
metabolic pathways are most immediately impacted by
LPS. The concentration ratio (Cit+Orn)/(Arg+Asp) was
most sensitive to LPS challenge, changing significantly at
lower concentrations and earlier times following LPS
treatment compared to total media NOx and other com-
monly used metabolic biomarkers of cellular methyla-
tion, redox, polyamine and nitrogen balance status
(Figure 3).Figure 4 Shifts in the macrophage CO/AA ratio temporally precede ch
levels. Temporal changes in the CO/AA ratio were plotted against other m
cells) were either left untreated or treated with 10 ng/ml LPS for 2, 4 or 6 h
SD; N = 6) were quantified as described in Methods. Panel A shows time-d
media nitrate/nitrite concentrations (NOx). * denotes statistical significanceBecause the CO/AA ratio significantly changed prior
to cellular GSH/GSSG redox change, it appears to be a
redox independent biomarker of macrophage activation.
Thus, simultaneous quantification of CO/AA and thiol
redox ratios allows for concurrent analysis of metabolic
shifts during cellular inflammation and oxidative stress.
Arginase and iNOS regulation
Results presented here reveal the importance of arginase
in iNOS regulation. LPS is known to acutely stimulate
iNOS within the first 24 hrs of macrophage activation
[11,46] and the induction of iNOS and subsequent NO
generation are critical to macrophage innate immune
functions [47]. In contrast, the role of arginase in iNOS
regulation during the initial phases of macrophage acti-
vation is less well understood. The ratio of Cit/Orn
increased linearly with LPS concentration, with maximal
effects observed at 10 ng/L, declining at 100 and 1000
ng/ml, due to the rise in Orn (Figure 2). These data sug-
gest that the relatively low sensitivity of arginase
enzymes to LPS at low concentrations allows for max-
imal rates of iNOS activity, but at higher LPS concentra-
tions, induction of arginase resulting in increased Orn,
may prevent the toxicity of excess NO generation. Argi-
nase inhibition therapy has been proposed to improve
endothelial function by increasing Arg available for NO
generation [48,49]. Results reported here suggest that
arginase activity differs depending on LPS burden, and
that arginase inhibition when LPS is high may exacer-
bate inflammation by excessive NO production.
Type I and Type II arginase isoforms
Results presented here suggest that Arg-derived metabo-
lites may be useful in determining the type of arginase
isoform expressed in cells [11]. Macrophage express
both type I and type II arginases. The type I (cytoplas-
mic) isoform is typically associated with the TH2 alter-
native macrophage activation pathway, which isanges in other amino acid metabolites and total media NOx
etabolic indices of macrophage activation. Briefly, RAW cells (2 × 106
rs. At each time point, cells were harvested and metabolites (mean ±
ependent changes in the ratios of CO/AA and GSH/GSSG, and total
( P <0.05).
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tion [9,49,50]. In contrast, the type II (mitochondrial)
form of arginase is induced only by TH1 classical activa-
tion, and is charcterized by the lack of polyamine and
proline production. LPS induces TH1 classical activation
and thus only type II arginase is induced [11]. Results
presented here are consistent with TH1 activation since
this increase was not accompanied by an increase in
spermidine, spermine, or proline (Table 2) , though Orn
was increased at very high LPS concentrations ( > 100
ng/ml). Thus, increased Orn/polyamine or proline ratios
may be indicative of arginase II induction whereas the
opposite may indicate arginase I induction. This sugges-
tion is plausible because the downstream enzymes for
polyamine and proline synthesis are cytosolic enzymes
and Orn synthesized in mitochondria may not feed into
these pathways.
A role for Asp in Arg synthesis in macrophage?
LPS-stimulated macrophage metabolize Arg at a greatly
enhanced rate, and therefore a continous supply of Arg
is needed by these cells to support their immune func-
tions. To meet this demand, LPS-activated macrophage
cells increase both the uptake and synthesis of Arg
[29,51,52]. In response to LPS (1 μg/ml) treatment
(Table 1 and Figure 2), the concentrations of Cit and
Orn, the two metabolic products of Arg, increased sig-
nificantly and greatly exceeded the amount of Arg loss
from levels found in untreated cells. As this was a
steady-state measurement, the extent of Arg loss in LPS
activated cells may underestimate the actual rate of Arg
uptake and resynthesis.
The cellular uptake of Arg is mediated by the cationic
amino acid transporter 2 (CAT2) [53]. CAT2 is coin-
duced with iNOS in LPS-treated macrophages [53]. In-
hibition of CAT2 decreases iNOS-dependent Cit/NO
generation without impacting the level of iNOS protein
abundance [53]. Although Arg is its preferred substrate,
CAT2 is also capable of transporting other cationic
amino acids, such as Orn and Lys, that can potentially
compete with Arg import and reduce Cit/NO output.
However, this is unlikey to be the case in this model be-
cause the concentration of Lys or Orn in the media was
far below the concentration required for competitive in-
hibition of Arg uptake and subsequent NO and/or Cit
synthesis [51,53].
Cit (produced along with NO from Arg) can
synthesize Arg by the combined actions of the arginino-
succinate synthetase (ASS) and argininosuccinate lyase
(ASL) [28]. ASS and ASL are known to increase in
RAW macrophage following LPS challenge [28,29,54].
Though Asp is required for Cit-dependent Arg synthesis
by the ASS/ASL pathway, a role for Asp in Arg synthesis
in macrophage has not been established. Although thisreport does not conclusively establish the metabolic fate
of Asp on LPS challenge, the large decrease in both Asp
and Arg (Table 1) suggest potential involvement of Asp
in Arg synthesis. The contribution of Asp to support
Arg-Cit-NO cycle may be particularly more important in
RAW macrophages because these cells may not contain
active carbamyl phosphate synthetase (CPS) or ornithine
transcarbamylase enzymes (OTC) required for convert-
ing other amino acids, such as Pro, to synthesize Cit and
Arg [29].
It should be noted that unlike plasma or other widely
used media such as RPMI, the DMEM media used in
this study lacks Ala, Pro, Glu, Asp and Asn. It is pos-
sible that this deficiency would have prevented the
utilization of these amino acids to regenerate Arg, that
would otherwise occur under amino acid replete condi-
tions. However, cellular biosynthesis of these non-
essential amino acids would also be expected, which
would be expected to mitigate any deficiency. While de-
ficiency could theoretical impact the rate of Arg replen-
ishment, this is unlikely to alter our major findings
because availability of these substrates do not directly
modulate LPS-dependent up-regulation of iNOS and
arginase expression.Oxidation of cellular GSH following LPS challenge occurs
secondary to iNOS activation
Oxidative stress modulates the LPS-dependent activation
of pro-inflammatory genes, including the iNOS protein
[55-57]. Nuclear Factor-kappa-light-chain-enhancer of
activated B cells (NFkB) is a key inflammatory transcrip-
tion factor responsible for up-regulating inflammatory
genes following LPS exposure [56]. LPS increases macro-
phage oxidant generation from multiple sources such as
mitochondria [58] and the NADPH oxidase enzyme
[59]. ROS mediated oxidation of critical thiol in MAP
kinase phosphatase-1, a key phosphatase enzyme in
macrophage cells, has been shown to be involved in the
activation of upstream MAP kinase proteins (p38, JNK,
and Erk1/2) responsible for NFkB activation [46]. Be-
cause of the potential role of oxidative stress in iNOS ac-
tivation, the oxidation of the GSH pool may precede
LPS-dependent NFkB activation. However, the analysis
here (Figure 4A) indicates that oxidation of cellular
GSH, following LPS challenge, occurs secondary to
increased Arg-Cit-NO pathway activity, as no significant
declines in GSH/GSSG ratios are observed during the
first 6 hrs following LPS addition. This result suggests
that the initial activation of iNOS does not require a
GSH redox pool oxidation. However, it is possible that
subsequent oxidation of the GSH pool may play a role
in propagation rather than the initiation of the LPS in-
flammation signaling.
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signaling?
In addition to GSH, LPS addition caused the elevation in
cellular Cys and Hcy. Cys and Hcy exert pro-oxidant
effects in cells by oxidizing protein thiols through S-
cysteinylation or S-homocysteinylation [12,16,60,61].
However, there is no evidence that Cys and Hcy have any
involvement in inflammatory signaling. The rise in Cys
and Hcy observed after LPS challenge (Table 1), can cause
oxidation of protein disulfides by means of mixed disulfide
formation. The potential role of Cys or Hcy-dependent S-
thiolation in macrophage redox signaling is currently un-
known. Given the reactivity of Cys and Hcy to protein S-
thiolation, the LPS-dependent increase in their levels, as
seen in this study, indicates that they may represent non-
oxidant mediated redox signaling mechanism.
Clinical implications
LPS has been implicated not only in sepsis but also as a
potential trigger of subclinical inflammation in obesity
and in cardiovascular diseases [62,63]. A possible mech-
anism for inflammation in these diseases may involve ac-
tivation of macrophage cells by low threshold grade LPS
(1 ng/ml), which cooperatively enhances the pro-
atherogenic effects of oxidized LDL [63]. Detection of
cellular effects of such low levels of LPS is challenging
and the metabolomics data presented indicate that the
OC/AA ratio is significantly increased in response to
low concentration of LPS (0.1 ng/ml) than existing bio-
markers (Figure 3). When combined with its ability to
monitor major physiological small molecule thiol redox
states, this assay may be useful in quantifying the onset
of sub-clinical inflammation mediated by monocytes/
macrophage cells.
Prospective human studies have shown that plasma
ratios of Arg/Cit + Orn is associated with increased risk
for developing adverse cardiovascular disease outcomes in
healthy adults and risk of morbidity and mortality in sickle
cell patients [64,65]. Plasma thiol redox perturbations
occur in the course of aging and development of age-
related diseases [12,16]. Inflammation in healthy indivi-
duals with or without oxidative stress may have different
clinical consequences. The ability to measure both pro-
cesses, as in this present study, may be clinically useful in
further clarifying the role of inflammation in disease. Dur-
ing its development phase, this assay was succesfully ap-
plied to monitor leukocyte oxidative stress in children
with austism spectrum disease [66], erythrocyte oxidative
stress in sickle cell patients [67], plasma and erythryocyte
oxidative stress in thalassemia patients [37], oxidative
stress in lung fibroblasts caused by cystic fibrosis conduct-
ance transporter mutation [68] and cigarette exposure
[69]. Inflammation in healthy individuals with or without
oxidative stress may have different clinical consequences.The ability to quantify shifts in both inflammation and
redox pathways, as presented in this paper, may be clinic-
ally useful in further clarifying the role of inflammation in
diseases.
Conclusions
Amino acid metabolism changes with activation states of
macrophage. However, few studies have explored the po-
tential of amino acid metabolites as sensitive biomarkers
for inflammation and redox stress. By comprehensively
quantifying Arg and SAAs and their metabolic inter-
mediates, the early metabolic shifts during macrophage
activation were established, and the CO/AA ratio was
identified as a new sensitive biomarker of macrophage
inflammation. Additionally, mechanistic insights into
how specific changes in Arg-Cit-NO Cycle relate to cel-
lular redox and polyamine balance were also suggested.
Specifically, data suggest that GSH redox loss is not
required for iNOS activation. The concentration-
dependent effects of LPS on Cit/Orn balance and polya-
mines suggests that activation of mitochondrial type II
arginase is required for preventing excessive iNOS activ-
ity, but does not result in increased cellular polyamine
content. It is suggested that monitoring macrophage
health in human plasma may permit early identification
of sub-clinical inflammation and oxidative stress.
Additional files
Additional file 1: Table S1. Mass spectrometric setting used in this
study.
Additional file 2: Figure S1. Effects of iodoacetamide (IAM)
pretreatment on cellular arginine (Arg), citrulline (Cit) and ornithine (Orn)
concentrations. The effects of iodoacetamide pretreatment on
intracellular Arg (Panel A), Cit (Panel B) and Orn (Panel C) concentration
are shown. RAW cells (2 × 106) were left untreated (control) or treated
with 0.1, 1, 10, 100 and 1000 ng/ml LPS (LPS) for 24 hrs at 37°C. For
extraction without IAM, cells were harvested and washed with phosphate
buffered saline and immediatedly treated with perchloric acid. For
extraction with IAM, cells were pre-incubated with IAM solution for 1 hr
prior to perchloric acid treatment. Metabolite concentrations were
normalized to protein concentrations. Results show no significant
differences between cells treated with or without IAM.
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